Ganymed’s IMAB362 Receives Orphan Designation

Ganymed Pharmaceuticals’ IMAB362 for the treatment of pancreatic cancer has been granted orphan drug designation by the FDA and EMA. IMAB362 is a monoclonal antibody currently in Phase IIb development for gastroesophageal cancer.
 
IMAB362 selectively binds to the protein CLDN18.2, which is expressed in approximately 60% of primary and metastatic pancreatic cancers and approximately 80% of gastroesophageal cancers, as well as other solid tumors. The drug represents an advantage in that CLDN18.2 is absent from the vast majority of healthy tissues and therefore only targets cancerous cells.